An Australian haematologist is backing time-limited therapy after his research showed long-term venetoclax (Venclexta) use could drive drug resistance in myeloid cells. A study of 89 chronic lymphocytic leukaemia (CLL) patients on median 75 months’ venetoclax showed prolonged BCL2 inhibitor use could give rise to anti-apoptotic myeloid BAX mutations — a potentially significant adaptation for ...
Myeloid venetoclax resistance observed in CLL patients
By Natasha Doyle
9 Sep 2021